Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
13 mars 2025 18h07 HE
|
Cellectis Inc.
○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD...
Allogeneic CAR-T Cell Patent Landscape and Forecast Report 2024-2032, Profiles of Artiva Biotherapeutics, Poseida Therapeutics, Nanjing Beiheng Biological Technology, NantCell, GC Cell, BMS, Compugen
13 mars 2025 11h02 HE
|
Research and Markets
Dublin, March 13, 2025 (GLOBE NEWSWIRE) -- The "Allogeneic CAR-T Cell Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering.The global allogenic...
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
07 mars 2025 16h30 HE
|
Cellectis Inc.
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Monthly information on share capital and company voting rights
06 mars 2025 16h30 HE
|
Cellectis Inc.
PARIS, March 06, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Market Research 2025: Global Advancements Poised to Transform Oncology Landscape
04 mars 2025 10h49 HE
|
Research and Markets
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. The Chimeric...
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
24 févr. 2025 01h30 HE
|
Cellectis Inc.
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
CAR T-Cell Therapy Market Forecasts to 2035, with Competitor Profiles of Autolus, Bluebird Bio, Carsgen Therapeutics, Cellectis, Noile-Immune Biotech, Shanghai GeneChem, Takara Bio and More
05 févr. 2025 07h45 HE
|
Research and Markets
Dublin, Feb. 05, 2025 (GLOBE NEWSWIRE) -- The "CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035" report has been added to ResearchAndMarkets.com's offering. The global CAR...
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
29 janv. 2025 16h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
17 janv. 2025 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
10 janv. 2025 08h00 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025